Robeco Institutional Asset Management B.V. reduced its holdings in Agilent Technologies, Inc. (NYSE:A – Get Rating) by 6.1% during the 3rd quarter, Holdings Channel reports. The fund owned 132,665 shares of the medical research company’s stock after selling 8,608 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Agilent Technologies were worth $16,125,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC increased its position in Agilent Technologies by 34.8% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 298 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 77 shares during the period. Edge Capital Group LLC increased its position in Agilent Technologies by 53.0% in the 3rd quarter. Edge Capital Group LLC now owns 303 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 105 shares during the period. Guardian Wealth Advisors LLC acquired a new stake in Agilent Technologies in the 3rd quarter valued at approximately $42,000. CVA Family Office LLC increased its position in Agilent Technologies by 722.2% in the 3rd quarter. CVA Family Office LLC now owns 370 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 325 shares during the period. Finally, Penserra Capital Management LLC acquired a new stake in Agilent Technologies in the 1st quarter valued at approximately $60,000.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on A shares. Evercore ISI lifted their price target on Agilent Technologies from $140.00 to $155.00 in a research report on Tuesday, November 22nd. Citigroup lifted their price target on Agilent Technologies from $145.00 to $150.00 and gave the company a “neutral” rating in a research report on Tuesday, November 22nd. UBS Group lifted their price target on Agilent Technologies from $152.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, December 20th. Wells Fargo & Company upgraded Agilent Technologies from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $150.00 to $170.00 in a research report on Tuesday, January 10th. Finally, Jefferies Financial Group lifted their price target on Agilent Technologies from $158.00 to $168.00 in a research report on Tuesday, November 22nd. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $163.31.
Agilent Technologies Stock Performance
Agilent Technologies (NYSE:A – Get Rating) last issued its earnings results on Tuesday, February 28th. The medical research company reported $1.37 EPS for the quarter, topping the consensus estimate of $1.31 by $0.06. The business had revenue of $1.76 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Agilent Technologies had a return on equity of 30.35% and a net margin of 19.09%. Agilent Technologies’s revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.21 earnings per share. As a group, sell-side analysts forecast that Agilent Technologies, Inc. will post 5.68 earnings per share for the current fiscal year.
Agilent Technologies Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 26th. Stockholders of record on Tuesday, April 4th will be given a $0.225 dividend. The ex-dividend date is Monday, April 3rd. This represents a $0.90 annualized dividend and a dividend yield of 0.68%. Agilent Technologies’s dividend payout ratio (DPR) is presently 20.32%.
Agilent Technologies announced that its Board of Directors has approved a stock buyback program on Monday, January 9th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 4.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.
About Agilent Technologies
Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.
- Get a free copy of the StockNews.com research report on Agilent Technologies (A)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A – Get Rating).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.